Novartis inks $1B-plus biobucks deal with Flagship’s Generate (September 24, 2024) | By Gabrielle Masson. Novartis has inked a deal potentially worth more than $1 billion with Flagship-founded Generate:Biomedicines to develop protein therapeutics across multiple indications. The companies did not disclose specifics about potential disease areas, referring only to the pact as a “multi-target collaboration”
Continue ReadingVIDEO: 9/24/2024 (September 24, 2024 ) | By Ross Youngs. Particle Accelerator Episode 22 With Ross Youngs Particle Accelerator Podcast: Innovating with Ross – 75 Patents & Counting! ð 75 patents across multiple industriesð¼ From waiter to Inc. 500 list & SBA Business Person of the Yearð¬ Pioneering microbiome mining & biotechnology innovations⚖️ David vs.
Continue ReadingScilex’s Semnur Pharmaceuticals to go public through $2.5B SPAC merger as it advances sciatica prospect (September 3, 2024) | By Zoey Becker. Semnur Pharmaceuticals, which is working on a non-opioid prospect for sciatica, has agreed to merge with special purpose acquisition company Denali Capital Acquisition Corp. in a deal worth $2.5 billion. Upon closure of
Continue Reading